[A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones and soft tissue]

Caballero-Villarraso J, Marquez-Pelaez S, Corbacho-Martin B, Palacios-Eito A
Record ID 32011000514
Spanish
Authors' recomendations: It was observed that there was great heterogeneity across the papers concerning the multiplicity of current uses of IMRT. Only three clinical trials out of 501 papers were retrieved from the search; two of them were focused on breast cancer, and one on SNC tumours (glioblastoma multiforme). The three of them had relevant sample sizes. They scored between 12 and 16 (out of 18) after being assessed with CASPe guideline; none of them analysed health-related quality of life (HRQL) by following the criteria of a standard scale; and only one of them studied survival. IMRT shows better outcomes than RT-2D, treatment with which the former is compared, as in this aspect of the said study on SNC tumours as in the whole set of studied variables in the three clinical trials. Thus the parameters related to acute and chronic toxicity, place-regional control of tumour, or pain and other parameters related to quality of life report better results in patients who were treated with IMRT. Other clinical studies were located (case control studies and case series) and planning studies which, generally speaking, reported the advantages of IMRT against other forms of RT. Conclusions: nowadays IMRT shows a wide range of utilities in treating many neoplasms, including the therapeutic one in breast cancer, SNC tumours and musculoskeletal sarcoma. The clinical trials in respect are scarce but have a good quality. The rest of papers based on health clinical experience, like theoretical designs, report superiority of IMRT over other radiotherapy treatments.
Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Breast Neoplasms
  • Radiotherapy, Intensity-Modulated
  • Sarcoma
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. InnovaciĆ³n, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.